1. Student, M.B.P. and B.S. Shadi Abdi, 2016. Prevalence of food insecurity in Iran: A systematic review and meta-analysis. Arch. Iran. Med., 19: 288-294.
   Direct Link  |  
2. Sadabad, H.N., M. Behzadifar, F. Arasteh, M. Behzadifar and H.R. Dehghan, 2016. Efficacy of platelet-rich plasma versus hyaluronic acid for treatment of knee osteoarthritis: A systematic review and meta-analysis. Electr. Phys., 8: 2115-2122.
   CrossRef  |  Direct Link  |  
3. Farhadi, Z., S. Alidoost, M. Behzadifar, R. Mohammadibakhsh and N. Khodadadi et al., 2016. The prevalence of migraine in Iran: A systematic review and meta-Analysis. Iran. Red Crescent Med. J., Vol. 18. 10.5812/ircmj.40061.
   CrossRef  |  
4. Behzadifar, M., M. Behzadifar, S. Abdi, M. Arabsalmani, M. Saroukhani and K. Sayehmiri, 2016. The role of socioeconomic status on health-related quality of life in the west of Iran. J. Clin. Diagnostic Res., 10: LC10-LC13.
   CrossRef  |  
5. Behzadifar, M., M. Behzadifar, M. Saroukhani, K. Sayehmiri and A. Delpisheh, 2016. Evaluation of effective indexes on quality of life related to health in western Iran in 2013. Iran. Red Crescent Med. J., Vol. 18. 10.5812/ircmj.23781.
   CrossRef  |  
6. Behzadifar, M., K.B. Lankarani, S. Abdi, M.T. Mirghaed and G. Beyranvand et al., 2016. Seroprevalence of hepatitis E Virus in Iran: A systematic review and meta-analysis. Middle East J. Digestive Dis., 8: 189-200.
   CrossRef  |  
7. Behzadifar, M., M. Mirzaei, M. Behzadifar, A. Keshavarzi, M. Behzadifar and M. Saran, 2015. Patients' experience of tuberculosis treatment using directly observed treatment, Short-Course (DOTS): A qualitative study. Iran. Red Crescent Med. J., Vol. 17. 10.5812/ircmj.17(4)2015.20277.
   CrossRef  |  
8. Behzadifar, M., M. Behzadifar, A. Sayehmiri, M. Behzadifar, M. Sarokhani and K. Sayehmiri, 2015. Economic factors influencing mental health using multiple regression model in Ilam province of Iran. Med. J. Islamic Republic Iran, Vol. 29. .
   Direct Link  |  
9. Behzadifar, M., H. Dehghan, K. Saki, M. Behzadifar, A. Keshavarzi, M. Saran and A.A. Sari, 2015. Evaluation efficacy and safety of vortioxetine 20 mg/d versus placebo for treatment major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Pharmacol. Pharm., 6: 221-231.
   Direct Link  |  
10. Behzadifar, M., H. Dehghan, K. Saki and K. Sayehmiri, 2015. Vortioxetine versus placebo for treatment of major depressive disorder. J. Basic Res. Med. Sci., 2: 31-41.
11. Behzadifar, M., A. Keshavarzi, A. Tofighian, M. Rastian, M. Zobidi and A.A. Sari, 2015. Efficacy and safety of vortioxetine and duloxetine 60 mg compared placebo for the treatment of major depressive disorder: A systematic review and meta-analysis. J. Behav. Brain Sci., 5: 430-439.